Sign in Subscribe
Drugs

Targeting V-1A-Vasopressin Receptors with SP-G: A New Strategy in Anti-Cancer Therapy

Strategic Insights

— 2 min read

In a groundbreaking study, researchers at the University of Edinburgh have discovered a novel approach to target small cell lung cancer cells using the anti-cancer agent [Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) (SP-G). This compound modulates gastrin releasing peptide (GRP) and arginine vasopressin signaling, leading to growth arrest and apoptosis in cancer cells. The study, published in the British Journal of Pharmacology, highlights the potential of SP-G as a biased agonist at the V-1A vasopressin receptor, offering a new strategy for anti-cancer therapy.

Key Takeaways:

  • SP-G acts as a biased agonist at the V-1A vasopressin receptor, causing a sustained activation of ERK via G(i) coupling.
  • Inhibition of Gi with Pertussis toxin attenuated the inhibition by SP-G of the growth of CHO-K1 cells stably expressing the V-1A receptor.
  • The second intracellular loop of the V-1A receptor is essential for vasopressin-stimulated PLC and ERK activation but not for SP-G-induced ERK activation.
  • Chimeric V-1A receptors containing the second or third intracellular loop of the V-2 receptor were capable of binding vasopressin and SP-G but had altered ability to activate PLC and ERK.
  • The study provides mechanistic insight into biased agonists at V-1A receptors and highlights their potential as anti-cancer agents.
  • SP-G has shown promise in targeting small cell lung cancer cells, leading to growth arrest and apoptosis.
  • The study was conducted by investigators in Scotland, led by A.C. Mackinnon and team at the University of Edinburgh.

Statistics:

  • The study focused on the V-1A vasopressin receptor, which is crucial for vasopressin-stimulated PLC and ERK activation.
  • SP-G caused a sustained activation of ERK via a stimulation of V-1A receptor coupling to G(i) in V-1A receptor expressing cells.
  • The study used activation state-specific antibodies and Fura-2-AM to measure extracellular regulated kinase (ERK) activation and intracellular Ca2+ respectively.
  • 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland is the address of the Center for Inflammat Research, Queensland Institute Med Research.
  • Nature Publishing Group, Macmillan Building, 4 Crinan St., London N1 9XW, England is the publisher of the British Journal of Pharmacology.

Sources:

  • British Journal of Pharmacology, 2009;156(1):36-47
  • University of Edinburgh, Center Inflammat Research, Queensland Institute Med Research, 47 Little France Crescent, Edinburgh EH16 4TJ, Midlothian, Scotland
  • Nature Publishing Group, Macmillan Building, 4 Crinan St., London N1 9XW, England

Read more